Our data translated these observations in the setting of CML, describing a novel Bcr-Abl/IκB-α/p53 network, with potentially relevant implications for both tumorigenesis and therapy. The gene discussed is NFKBIA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.